EEG, MAO-A inhibition, pharmacokinetics and safety of befloxatone in the elderly

Human Psychopharmacology

Volumn 12, Issue 6, 1997, Pages 557-571

  Patat, Alain ^a   Dubruc, Catherine ^b   Deschamp, Claire ^b   Durrieu, Geneviève ^b   Trocherie, Suzanne ^d   Cimarosti, Isabelle ^a   Allain, Hervé ^c   Rosenzweig, Pierre ^b   Gandon, Jean Marc ^a  

^a Biotrial SA   (France)

^b SANOFI   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Antidepressant; Befloxatone; EEG; Elderly; MAO A inhibitor

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BEFLOXATONE; MONOAMINE OXIDASE A INHIBITOR; NORTRIPTYLINE; PLACEBO;

AGED; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ELECTROENCEPHALOGRAM; ENZYME INACTIVATION; FEMALE; HEADACHE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; VOMITING;

EID: 0031474230     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199711/12)12:6<557::AID-HUP923>3.0.CO;2-P     Document Type: Article

References (49)

1. Ansseau, M., Caille, P., Derks, C., Cieren-Puiseux, I., Wauthy, J., Ego, D., Curet, O., Thiola, A., Rovei, V. and Jarreau, F. X. (1992). Phase 1 study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant. Clinical Neuropharmacology, 15(S1), 328B.
2. Ascalone, V. and Dal Bo, L. (1987). Determination of amitriptyline, chlorimipramine and their demethylated metabolites in plasma by normal phase HPLC and UV detection. In: Development in Analytical Methods in Pharmaceutical, Biomedical and Forensic Sciences, Piemonte, G., Tagliano, F., Marigo, M. and Frigenio, A. (Eds), Plenum Publishing Corporation, New York, pp. 233-239.
3. Bieck, P. R. and Antonin, K. H. (1994). Tyramine potentiation during treatment with MAOIs. In: Progress in Psychiatry, Vol. 43, Clinical Advances in Monoamine Oxidase Inhibitor Therapies, Kennedy, S. H. (Ed.), American Psychiatry Press Inc, Washington DC, pp. 83-110.
4. Blackwell, B., Marley, E., Price, J. and Taylor, D. (1967). Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. British Journal of Psychiatry, 113, 349-365.
5. Cann-Moisan, C., Caroff, J., Le Bras, P., Girin, E., Curet, O. and Gandon, J. M. (1996). Measurement of 3-4 dihydroxyphenyl ethylene glycol (DOPEG) in plasma by high-performance liquid chromatography with electrochemical detection. Journal of Liquid Chromatography and Related Technology, 19(19), 3119-3124.
6. Coppola, R. and Herrmann, W. M. (1987). Psychotropic drug profiles: comparisons by topographic maps of absolute power. Neuropsychobiology, 18, 97-104.
7. Court, L. A., Laget, P., Bassant, M. H. and Dufour, R. (1971). Analyse Mathématique de l'Activité Électrique Cérébrale Spontanée. Actualités Neurophysiologiques. Masson, Paris, pp. 54-93.
8. Curet, O., Damoiseau, G., Labaune, J. P., Rovei, V. and Jarreau, F. X. (1994). Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monomaines in freely moving rats. Journal of Neural Transmission, 41, 349-355.
9. Deptula, D. and Pomara, N. (1990). Effects of antidepressants on human performance: A review. Journal of Clinical Psychopharmacology, 10(2), 105-111.
10. Fink, M. (1978). EEG and psychopharmacology. Electroencephalography and Clinical Neurophysiology, 45, 41-46.
11. Fitton, A., Faulds, D. and Goa, L. (1992). Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs, 43(4), 561-596.
12. Goldman, L. S., Alexander, R. C. and Luchins, D. J. (1986). Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. Journal of Clinical Psychiatry, 47, 225-229.
13. Herrmann, W. M. (1982). Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs. In: EEG in Drug Research, Herrmann, W. (Ed.), Gustav Fisher Verlag, Stuttgart, pp. 249-351.
14. Herrmann, W. M., Schärer, E. and Delini-Stula, A. (1991a). Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine. Pharmacopsychiatry, 24, 196-205.
15. Herrmann, W. M., Schärer, E., Wendt, G. and Delini-Stula, A. (1991b). Pharmaco-EEG profile of levoprotiline: second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry, 24, 206-213.
16. Herrmann, W. M., Schärer, E., Wendt, G. and Delini-Stula, A. (1991c). Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry, 24, 214-224.
17. Hindmarch, I. (1980). Psychomotor function and psychoactive drugs. British Journal of Clinical Pharmacology, 10, 189-209.
18. Hindmarch, I. and Kerr, J. (1992). Behavioral toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology, 106, 549-555.
19. Itil, T. M., Bhattachyaryya, A., Polvan, M., Huque, M. and Menon, G. N. (1977). Fluvoxamine (DU23000) a new antidepressant. Quantitative pharmaco-electro-encephalography and pilot clinical trials. Progress in Neuropsychopharmacology, 1, 309-348.
20. Itil, T. M., Menon, G. N. and Itil, K. Z. (1982). Computer EEG drug data base in psychopharmacology and in drug development. Psychopharmacology Bulletin, 18, 165-172.
21. Itil, T. M., Mukherjee, S., Dayican, G., Shaw, G. and Itil, K. Z. (1988). Mode of action and dose finding of sertraline, a new antidepressant based on CEEG-brain mapping technology. Psychopharmacology, 96, 281.
22. Laurian, S., Gaillard, J. M., Le, P. K. and Schöpf, I. (1983). Topographic aspects of EEG profile of some psychotropic drugs. Advances in Biological Psychiatry, 13, 165-171.
23. Lecrubier, Y. (1994). Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Safety, 10(4), 292-300.
24. Luthringer, R., Dago, K. T., Patat, A., Caille, P., Curet, O., Durrieu, G., Rinaudo, G., Toussaint, M., Granier, L. A. and Macher, J. P. (1996). Pharmaco-electro-encephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Neuropsychobiology, 34, 98-105.
25. Marley, E. and Blackwell, B. (1970). Interactions of monoamine oxidase inhibitors, amines and foodstuffs. Advances in Pharmacology and Chemotherapy, 8, 185-239.
26. Martin, L., Bakish, D. and Joffe, R. (1994). MAOI treatment of depression. In: Progress in Psychiatry, Vol. 43, Clinical Advances in Monoamine Oxidase Inhibitor Therapies, Kennedy, S. H. (Ed.), American Psychiatric Press Inc., Washington DC, pp. 147-180.
27. McClelland, G. R. and Raptopoulos, P. (1984). EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers. Psychopharmacology, 83, 327-329.
28. McClelland, G. R., Raptopoulos, P. and Jackson, D. (1989). The effect of paroxetine on the quantitative EEG. Acta Psychiatrica Scandinavica, 80 (Suppl.), 50-52.
29. Murphy, D. L., Aulakh, C. S., Carrick, N. A. and Sunderland, T. (1987). Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychology of the affective disorders and some related disorders. In: Psychopharmacology: The Third Generation of Progress, Meltzer, H. Y. (Ed.), Raven Press, New York, pp. 545-552.
30. Pare, C. M. B. (1985). The present status of monoamine oxidase inhibitors. British Journal of Psychiatry, 146, 576-584.
31. Patat, A., Berlin, I., Durrieu, G., Armand, P., Fitoussi, S., Molinier, P. and Caille, P. (1995a). Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor in healthy subjects. Journal of Clinical Pharmacology, 35, 633-643.
32. Patat, A., Gandon, J. M., Durrieu, G., Raoul, P., Le Cox, F., Beck, A., Curet, O., Cimarosti, I. and Allain, H. (1995b). Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects. Human Psychopharmacology, 10, 111-125.
33. Patat, A., Gandon, J. M., Le Coz, F., Durrieu, G., Cimarosti, I., Allain, H. and Rosenzweig, P. (1995c). Effects of befloxatone on psychomotor and cognitive functions in elderly subjects. European Neuropsychopharmacology, 5(3), 316.
34. Patat, A., Le Coz, F., Gandon, J. M., Durrieu, G., Cimarosti, I., Jezequel, S., Curet, O., Dubruc, C., Zieleniuk, L, Allain, H. and Rosenzweig, P. (1996). Pharmacodynamics and pharmacokinetics of two dosage regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. Journal of Clinical Pharmacology, 36, 216-229.
35. Patat, A., Trocherie, S., Thebault, J. J., Rosenzweig, P., Dubruc, C., Bianchetti, G., Morselli, P. L. and Court, L. A. (1994). EEG profile of litoxetine after single and repeated administration in healthy volunteers. British Journal of Clinical Pharmacology, 37, 157-163.
36. Quitkin, F. M., Rothschild, R., Stewardt, J. W., McGrath, P. J. and Harrison, W. M. (1994). Atypical depression: A unipolar depressive subtype with preferential response to MAOIs (Columbia University Depressive Studies). In: Progress in Psychiatry, Vol. 43, Clinical Advances in Monoamine Oxidase Inhibitor Therapies, Kennedy, S. H. (Ed.), American Psychiatric Press Inc., Washington DC, pp. 181-203.
37. Reimann, I. W., Jobert, M., Gleiter, C. H., Turri, M., Bieck, P. R. and Herrmann, W. M. (1996). Different modes of data processing and statistical testing applied to the same set of pharmaco-EEG recordings: Effects on the evaluation of a selective and reversible MAO-A inhibitor (brofaromine). Neuropsychobiology, 33(3), 160-163.
38. Remaekers, J. G., Muntjewerff, N. D., Uiterwijk, M. M. C., van Veggel, L. M. A., Patat, A., Durrieu, G. and O'Hanlon, J. F. (1996). A study of the pharmacodynamic interaction between befloxatone and ethanol on performance and mood in healthy volunteers. Journal of Psychopharmacology, 10(4), 288-294.
39. Rovei, V., Benavides, J., Caille, D., Curet, O., Depoortere, M., Ego, D., Patat, A. and Scatton, B. (1994a). Biochemical pharmacology of befloxatone, a reversible selective and competitive inhibitor of MAO-A. Neuropsychopharmacology, 10(35), 3005.
40. Rovei, V., Caille, D., Curet, O., Ego, D. and Jarreau, F. X. (1994b). Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. Journal of Neural Transmission, 41, 339-347.
41. Saletu, B. (1987). The use of pharmaco-EEG in drug profiling. In: Human Psychopharmacology: Vol. 1, Measures and Methods; Hindmarch, I. and Stonier, P. D. (Eds), John Wiley and Sons, Chichester, pp. 173-200.
42. Saletu, B. and Grunberger, J. (1985). Classification and determination of the cerebral bioavailability of fluoxetine: pharmacokinetic, EEG and psychometric analysis. Journal of Clinical Psychiatry, 46, 45-52.
43. Saletu, B. and Grunberger, J. (1988). Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects. Journal of Clinical Psychiatry, 49, 59-71.
44. Saletu, B., Grunberger, J. and Linzmayer, L. (1986). On central effects of serotonin reuptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimeldine. Journal of Neural Transmission, 67, 241-266.
45. Saletu, B., Grunberger, J. and Rajna, P. (1983). Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. British Journal of Clinical Pharmacology, 15, 369-384.
46. Schenk, G. K., Giller, W. and Rouft, W. (1981). Double-blind comparisons of a selective serotonin reuptake inhibitor, zimeldine and placebo on quantified EEG parameters and psychological variables. Acta Psychiatrica Scandinavica, 63, 303-313.
47. Shulz, P., Dick, P., Blaschke, T. F. and Hollister, L. (1985). Discrepancies between pharmacokinetic studies of amitriptyline. Clinical Pharmacokinetics, 10, 257-268.
48. Volz, H.-P., Gleiter, C. H., Waldmeier, P. C., Struck, M. and Möller, H.-J. (1996). Brofaromine - a review of its pharmacological properties and therapeutic use. Journal of Neural Transmission, 103, 217-245.
49. Warot, D., Berlin, I., Patat, A., Durrieu, G., Zieleniuck, I. and Puech, A. J. (1996). Effects of befloxatone, a reversible, selective MAO-A inhibitor on psychomotor functions and memory in healthy subjects. Journal of Clinical Pharmacology, 1996.